Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1057/22 (Fish oil and juice for the treatment of cancer/SMARTFISH) 24-04-2024
Facebook X Linkedin Email

T 1057/22 (Fish oil and juice for the treatment of cancer/SMARTFISH) 24-04-2024

European Case Law Identifier
ECLI:EP:BA:2024:T105722.20240424
Date of decision
24 April 2024
Case number
T 1057/22
Petition for review of
-
Application number
14726214.1
IPC class
A23L 5/00
A61K 35/00
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 348.64 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

USE OF A COMPOSITION COMPRISING FISH OIL AND JUICE FOR THE TREATMENT AND/OR POST TREATMENT OF CANCER

Applicant name
Smartfish AS
Opponent name
N.V. Nutricia
Board
3.3.09
Headnote
-
Relevant legal provisions
European Patent Convention Art 56
European Patent Convention Art 83
European Patent Convention Art 100(a)
European Patent Convention Art 100(b)
European Patent Convention Art 123(2)
Rules of procedure of the Boards of Appeal Art 12(4)
Keywords

Auxiliary request 24 - admitted (yes)

Amendments - added subject-matter (no)

Therapeutic use - applicability of T 609/02

Sufficiency of disclosure - (yes)

Inventive step - (yes)

Catchword
The facts underlying T 609/02 should be taken into account when considering its findings for its applicability to the case at hand (Reasons 3.2.8 to 3.2.12).
Cited decisions
G 0002/21
T 0609/02
T 0117/04
T 0950/13
T 2059/13
T 2627/17
Citing decisions
-

I. The proprietor (appellant) lodged an appeal against the opposition division's decision revoking the patent.

II. With its notice of opposition, the opponent had requested that the patent be revoked on the grounds for opposition under Article 100(a) EPC (lack of novelty and lack of inventive step) and Article 100(b) EPC.

III. The opposition division decided, inter alia, that the subject-matter of claim 1 of the then main request met the requirements of Article 123(2) EPC but lacked novelty over D15 (D16 being an English translation of D15). The then auxiliary requests 3 to 6 were not admitted into the proceedings. The subject-matter claimed in the other then auxiliary requests was considered to be insufficiently disclosed.

IV. With its statement setting out the grounds of appeal, the appellant filed a number of claim requests. In response to the board's communication under Article 15(1) RPBA, it withdrew all but auxiliary requests 24 to 47.

V. Claim 1 of auxiliary request 24 reads as follows:

"A composition comprising a combination of fish oil and juice in an oil-in-water emulsion, for the use in treatment of cancer, wherein said fish oil is selected from fish oil having a totox value below 20 and omega-3 content above 10% by weight based on the total weight of the fish oil and wherein a suitable emulsifier is used to stabilize the emulsion, wherein the cancer types treated are selected from the group consisting of pancreatic cancer and neurological cancer."

Claims 2 to 11 are dependent claims.

VI. The following documents were cited in the case at hand:

D12: WO 2009/120091 A1

D14: J. Ferlay et al., "Cancer incidence and mortality

patterns in Europe: Estimates for 40 countries in

2012", European Journal of Cancer 49, 2013,

1374-403

D15: "Spis smart ved kreft", an article of Smartfish

AS, published on "bramat.no" on 23 November 2013

D16: English translation of D15 having the title "Eat

smart with cancer"

D18: Product information "Smartfish Nutrifriend 1100"

D27: Declaration of Janne Sande Mathisen, including

cell proliferation tests of pancreatic cancer

cells

VII. The parties' relevant arguments, submitted in writing and during the oral proceedings, are reflected in the reasons for the decision below.

VIII. Requests

The appellant requested that the decision under appeal be set aside and that the patent be maintained on the basis of one of auxiliary requests 24 to 47, filed with the statement setting out the grounds of appeal.

The opponent (respondent) requested that the appeal be dismissed.

1. Admittance of auxiliary request 24

1.1 The respondent submitted that auxiliary request 24 should not be admitted into the appeal proceedings. The respondent's main argument was that the appellant had many opportunities in the first-instance proceedings to file an auxiliary request having the limitation to the treatment of only pancreatic cancer and neurological cancer as claimed in auxiliary request 24.

1.2 For the following reasons, the board admitted this auxiliary request.

1.2.1 Claim 1 of auxiliary request 24 includes the feature "for the use in treatment of [...] pancreatic cancer and neurological cancer" (see point IV. above). In comparison to the higher-ranking claim requests which were withdrawn after the board had issued its communication under Article 15(1) RPBA, the post treatment of cancer has been deleted, and the number of cancers to be treated by the composition was significantly reduced.

1.2.2 Auxiliary request 24 was not filed in the first-instance proceedings. Filing it with the grounds of appeal is therefore an amendment to the appellant's appeal case within the meaning of Article 12(4) RPBA, the admittance of which is at the discretion of the board.

1.2.3 The board does not consider deleting the post treatment of cancer and limiting the treatment to only two types of cancer to be complex. Nor does this amendment lead to other complex considerations. On the contrary, these amendments narrow the scope of claim 1 and simplify the contentious issues discussed in the first-instance proceedings. For instance, this amendment restores novelty over D16 and limits the scope of claim 1 to only two types of cancer which are mentioned in tests according to examples 2 and 4 of the patent. The board finds that this amendment is suitable for addressing the issues which led to the decision under appeal, in particular for the assessment of sufficiency of disclosure. In view of the limitation of the scope of claim 1, its admittance is also not detrimental to procedural economy.

1.2.4 The board does not see that auxiliary request 24 should have been submitted in the first-instance proceedings. Under the current circumstances, the board does not see that the appellant was prompted by the course of the first-instance proceedings to file auxiliary request 24 before the opposition division.

In view of the above, auxiliary request 24 is admitted into the appeal proceedings.

2. Article 123(2) EPC

Claim 1 of auxiliary request 24 is based on a combination of claims 1 and 2 of the application as filed, where the post treatment of cancer mentioned in claim 1 is deleted, and the list of cancer types targeted by the treatment of cancer mentioned in claim 2 is limited to pancreatic cancer and neurological cancer. This deletion in the list of alternatives in claim 2 is merely the deletion in one list which is not objectionable under Article 123(2) EPC.

In view of the above, the subject-matter of claim 1 of auxiliary request 24 complies with the requirement under Article 123(2) EPC.

3. Sufficiency of disclosure

3.1 The respondent argued that the claimed subject-matter did not meet the requirement of Article 83 EPC since it was not plausibly demonstrated that the claimed therapeutic effects were achieved over the whole claimed range. It argued that it had not been shown that any type of juice when used in combination with fish oil was suited to providing the claimed therapeutic effects. There was no guidance in the application as filed on which of these juices, when combined with fish oil, promoted anti-cancer effects. It was also problematic that Nutrifriend 1100 as used in example 1 of the patent contained not only fish oil and juice but the additional components (i) protein isolate from milk, (ii) pectin, (iii) aroma from jackfruit, (iv) rosemary extract, (v) vitamin E, (vi) vitamin D and (vii) soya lecithin, which were known to be bioactive. The skilled person did not have any information from the application as filed to render it plausible that the alleged effects were the result of using fish oil and juice only. The respondent agreed with the opposition division that it was impossible to delineate any therapeutic effect induced by fish oil and the mixtures of juices from these additional bioactive components of Nutrifriend 1100, let alone to draw the conclusion that any juice and fish oil combination would provide the alleged therapeutic effects. In view of the above, there were serious doubts that the invention could be carried out over the whole claimed range. Thus, in its view, the invention could not be carried out by a skilled person over the whole claimed range.

3.2 For the following reasons, the board disagrees.

3.2.1 The board shares the appellant's view that the application as filed contains data on the anti-tumour activity of a composition according to claim 1 (Nutrifriend 2000) on neurological cancer cells (example 2) and on pancreatic cancer cells (example 4). This was confirmed by the opposition division (see point 11.3.2.1, the last eight lines on page 18 of the decision) and was not contested by the respondent.

3.2.2 The respondent substantially criticised the breadth of claim 1 with respect to the feature "juice", which was broadly defined, and it submitted that it was not plausible that any juice was successful in treating the two types of cancer defined in claim 1.

3.2.3 However, there is clear guidance on page 6, lines 11 to 15 of the application as filed (see also paragraph [0025] of the patent) that juices from fruits or berries having a high level of antioxidants, preferably from fruits having a minimum level of metal ions functioning as oxidising agent, may be used in the claimed composition. On page 6, lines 17 to 25 of the application as filed (see also paragraph [0026] of the patent), a comprehensive list of suited juices is given, so a skilled person is provided with ample guidance on the juices which may be used in the claimed composition. Nutrifriend 2000 as used in examples 2 and 4 contains apple, pear, pomegranate and aronia juices. All these juices are indicated in the application (and in the patent) as filed as preferred juices.

3.2.4 Moreover, there is no evidence on file to support the respondent's allegation that choosing any of these explicitly proposed juices might fail to achieve the claimed therapeutic effects. The respondent has not submitted any such evidence, for example, in the form of experimental data. In this context, the board disagrees with the statement given in the decision under appeal that a skilled person would not know which juice to choose. As outlined above, the board is of the opinion that a skilled person is provided with ample guidance as to suitable juices to be used.

3.2.5 Even though the additional components protein isolate from milk, pectin, aroma from jackfruit, rosemary extract, vitamin E, vitamin D and soya lecithin, which are present in Nutrifriend 2000 as well, are known to be bioactive and some also possess anti-cancer properties, this alone is not suited to raise serious doubts that the claimed therapeutic effects can be achieved when using only fish oil and juice. In the board's view, the respondent's converse conclusion is an unsubstantiated assertion.

3.2.6 In addition, it can be taken from example 4 that an increased apoptosis of pancreatic cancer cells by natural killer (NK) cells is achieved by Nutrifriend 2000 (a composition falling within the scope of claim 1) compared with the control and with the administration of the omega-3 fatty acid docosahexaenoic acid (DHA) alone (see Table 1 of the patent). However, Table 1 also shows that the omega-3 fatty acid DHA alone, which is a crucial ingredient of fish oil, leads to a slight increase in apoptosis of pancreatic cancer cells by NK cells. Under these circumstances, it is credible from the information given in the application as filed that also the claimed combination of fish oil and juice leads to the claimed therapeutic effects (see G 2/21, Reasons 74).

3.2.7 The therapeutic effect in connection with pancreatic cancer cells is further supported by evidence D27, which shows that fish oil alone (Denomega, the same fish oil as used in Nutrifriend 1100) and a combination of fish oil (Denomega) and a juice lead to a slight suppression of cell proliferation of pancreatic cancer cells, whereas a composition falling within claim 1 (Nutrifriend 1100) shows a significant suppression of pancreatic cancer cell proliferation. Evidence D27 filed after the filing date of the patent merely supplements the information provided in the application as filed (see example 4). D27 is not necessary to consider credible the claimed therapeutic effects (see G 2/21, Reasons 77), it only supports that conclusion.

3.2.8 The respondent presented two additional submissions that warrant consideration. First, it cited decision T 609/02 to bolster its challenge under Article 83 EPC, claiming its findings should apply to the current case. Second, it argued that the totox value specified in claim 1 is meaningless. However, both submissions are unconvincing for the following reasons.

3.2.9 Decision T 609/02 was quoted in G 2/21 (see Reasons 75) and several other decisions of the boards. For therapeutic use claims, the boards have derived from T 609/02 the principle that for Article 83 EPC to be complied with, the suitability for the claimed therapeutic use, unless already known to the skilled person at the priority date, must be disclosed by the application (see T 609/02, Reasons 9 and the Case Law of the Boards of Appeal, 10th ed. II.C.7.2.1). The reference to this decision cannot, however, change the assessment made by the current board because the facts are different. In the case underlying T 609/02, there was no evidence in the patent (or the application as filed) that the alleged effect took place. Furthermore, the application was also silent on the identification of the compound allegedly providing the effect (Reasons 5).

3.2.10 The opposite is true in the current case. The patent (and the application as filed) contains examples of the therapeutic uses claimed (see examples 2 and 4). Additionally, the composition providing the effect is clearly identified (see current claim 1). As a consequence, the board does not find that the invention was "made at a date later than the effective date of the patent" (see T 609/02, Reasons 8).

3.2.11 The board also notes that in several decisions of the boards, it was stated that the facts underlying decision T 609/02 differed from the facts underlying the respective cases judged in these decisions (T 117/04, Reasons 25; T 950/13, Reasons 3.9.1; T 2627/17, Reasons 2.1.3). While it is true, as held in T 2059/13, that differences in facts on which decisions are based are normal and the usefulness of case law is not confined to similar or identical facts (see Reasons 4.2.3), the current board is of the opinion that the facts underlying T 609/02 should be taken into account when considering its findings for its applicability to the case at hand.

3.2.12 The board thus concludes that the rationale underlying T 609/02 is not at odds with this board's finding of compliance with Article 83 EPC.

3.2.13 Concerning the totox value defined in claim 1, the board is of the opinion that a skilled person knows how to determine the totox value of fish oil. The totox value is a feature limiting the fish oil to be selected for the claimed composition. There is clear guidance in the application as filed to select a fish oil having an appropriate quality, i.e. having a low level of oxidation. As can be taken from page 5, lines 30 to 34 of the application as filed, to be of appropriate quality, the level of oxidation given as the totox value (two times the peroxide value added to the anisidine value) should be below 20, preferably below 10. Such fish oils of appropriate quality are usually clear oils with a very mild fishy odour and taste. Thus, even though for fish oil having a strong colour or fish oil containing added flavourings, such as virgin salmon oil containing carotenoids, the p-anisidine test would not be appropriate for measuring secondary oxidation in omega-3 oils, and consequently also the totox value could not be properly determined, there is clear guidance in the patent that clear oils, such as fish oil from cod, should be used, these oils not suffering from this problem.

In view of the above, the subject-matter of claim 1 of auxiliary request 24 meets the requirement of Article 83 EPC.

4. Inventive step

4.1 The respondent argued that the claimed subject-matter did not involve an inventive step in view of D12, D16 or D18 as the closest prior art taken in combination with D14.

4.2 The board disagrees for the following reasons.

4.2.1 D12 relates to a therapeutic drink comprising fresh marine oil having a totox value below 10 and further added antioxidants in an oil-in-water emulsion for the production of a medical preparation for the prophylaxis or treatment of diseases associated with elevated oxidative stress, such as cancer (see claim 1 and page 6, lines 11 to 15 of D12). The water phase may be a juice base (see claim 8 of D12).

4.2.2 D16 and D18 both concern a document on the drinkable juice Nutrifriend 1100 (as also used in example 1 of the patent). Nutrifriend 1100 is an oil-in-water emulsion comprising fish oil having a totox value below 20 and an omega-3 content above 10% by weight (based on the total weight of the fish oil) and an emulsifier. Nutrifriend 1100 is proposed for treating colon cancer, prostate cancer and cachexia in D16 and for treating cachexia in D18.

4.2.3 The subject-matter of claim 1 of auxiliary request 24 differs from each of documents D12, D16 and D18 in that none of these documents mention pancreatic cancer or neurological cancer. D12 only mentions the "treatment of cancer" in general, D16 mentions colon and prostate cancer as well as cancer cachexia, and D18 mentions cancer cachexia.

4.2.4 The objective technical problem is the provision of an alternative treatment of cancer.

4.2.5 On obviousness, the board comments as follows.

D12 does not mention pancreatic cancer or neurological cancer. D12 also fails to render it obvious that the composition disclosed in D12 might be suited for treating these types of cancer. A skilled person would not reasonably expect that any type of cancer could be treated by the drink taught in D12. The combination document D14 is a report on cancer incidence and mortality patterns in Europe which would not have taught the skilled person anything about whether the composition of D12 would have been an effective treatment for pancreatic cancer and neurological cancer either.

For similar reasons, the board is not convinced by the respondent's inventive-step objection starting from D16 or D18 as the closest prior art in combination with D14. Neither D16 nor D18 teaches or suggests that the composition Nutrifriend 1100 might be suited for the treatment of pancreatic cancer and neurological cancer. Different types of cancer require different treatments. In the absence of any further technical explanations, a therapeutic effect for one type of cancer cannot be simply extrapolated to other types of cancer. As outlined above, D14 does not provide any teaching which rendered the claimed therapeutic effects obvious for a skilled person.

4.2.6 The respondent argued that due to the information given in paragraph [0045] of the patent as granted, the treatment of cancer still included the treatment of cachexia.

The board does not interpret claim 1 in such a way. Claim 1 is limited to the treatment of two types of cancer, and it is no longer directed to the treatment of cachexia. While the treatment of cachexia was covered by claim 1 of the patent as granted, it is no longer claimed in auxiliary request 24.

In view of the above, the subject-matter of claim 1 of auxiliary request 24 involves an inventive step in view of D12, D16 or D18 as the closest prior art.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the claims according to auxiliary request 24 filed with the statement setting out the grounds of appeal and a description to be adapted and figures possibly to be adapted.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility